Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight
July 10, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 10, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight The prevalence of triple-negative breast...
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
May 02, 2023 08:15 ET
|
Qualigen Therapeutics, Inc.
Abstracts Feature Preclinical Data in (1) Pancreatic Cancer and (2) Luminal B Breast Cancer CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a...
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
April 18, 2023 07:30 ET
|
Qualigen Therapeutics, Inc.
In Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen”...
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
March 15, 2023 09:05 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
December 23, 2022 08:00 ET
|
Immutep Limited
Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population...
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
November 14, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete...
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
August 01, 2022 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
October 04, 2021 17:34 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
August 17, 2021 21:26 ET
|
Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...
Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study
November 05, 2019 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in...